Suppr超能文献

1α(OH)维生素D3会使正在服用氢氧化铝的血液透析患者血浆铝含量升高。

1 alpha(OH) vitamin D3 increases plasma aluminum in hemodialized patients taking AI(OH)3.

作者信息

Demontis R, Leflon A, Fournier A, Tahiri Y, Herve M, Moriniere P, Abdull-Massih Z, Atik H, Belbrik S, Renaud H

出版信息

Clin Nephrol. 1986 Sep;26(3):146-9.

PMID:3769230
Abstract

1 alpha(OH) vitamin D3 at the dose of 6 micrograms per week was given for 4 weeks to 16 stable patients on chronic hemodialysis with a low dialysate aluminum while taking a constant dose of Al(OH)3. A significant increase of their plasma aluminum was observed from 1.2 +/- .25 mumol/l before 1 alpha(OH)D3 to 1.7 +/- .35 during the second fortnight of 1 alpha(OH)D3 administration and this increase surprisingly was maintained at 1.71 +/- .3 up to 6 weeks after 1 alpha(OH)D3 discontinuation. Increases in plasma calcium and decreases in plasma PTH were observed during 1 alpha(OH)D3 administration and these changes were correlated to the changes in plasma aluminum. It is concluded that the increase in plasma aluminum observed with 1 alpha(OH)D3 and after its discontinuation is either due to body aluminum burden redistribution or to increased aluminum intestinal absorption whatever the mechanism is, this effect should lead to close monitoring of plasma aluminum in uremic patients taking 1 alpha OH vitamin D3.

摘要

每周给予16例慢性血液透析稳定患者6微克剂量的1α(OH)维生素D3,持续4周,这些患者透析液铝含量低,同时服用恒定剂量的氢氧化铝。观察到他们的血浆铝显著增加,从服用1α(OH)D3前的1.2±0.25微摩尔/升增加到服用1α(OH)D3第二周的1.7±0.35微摩尔/升,令人惊讶的是,在停用1α(OH)D3后6周,这一增加仍维持在1.71±0.3。在服用1α(OH)D3期间观察到血浆钙增加和血浆甲状旁腺激素降低,这些变化与血浆铝的变化相关。得出的结论是,服用1α(OH)D3时及停药后观察到的血浆铝增加,要么是由于体内铝负荷重新分布,要么是由于铝的肠道吸收增加,无论其机制如何,这种效应都应导致对服用1α-OH维生素D3的尿毒症患者的血浆铝进行密切监测。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验